Prelude Therapeutics Incorporated
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
/ 
Frequently asked questions
To buy Prelude Therapeutics Incorporated stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Prelude Therapeutics Incorporated by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Prelude Therapeutics Incorporated is PRLD:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Prelude Therapeutics Incorporated has its primary listing on NASDAQ. You can trade Prelude Therapeutics Incorporated with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Prelude Therapeutics Incorporated is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Prelude Therapeutics Incorporated as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Prelude Therapeutics Incorporated.